Results 351 to 360 of about 263,255 (408)

Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. [PDF]

Hum Mol Genet
Bajikar SS, Sztainberg Y, Trostle AJ, Tirumala HP, Wan YW, Harrop CL, Bengtsson JD, Carvalho CMB, Pehlivan D, Suter B, Neul JL, Liu Z, Jafar-Nejad P, Rigo F, Zoghbi HY.   +14 more
europepmc   +1 more source

Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling. [PDF]

J Neuromuscul Dis
Yavas A, van Putten M, Aartsma-Rus A.
europepmc   +1 more source

MALT1: The Dual Domains Drive Resistance to Immune Checkpoint Inhibitors

MedComm – Future Medicine, Volume 4, Issue 2, June 2025.
Haoze Xie, Jie Zhang, Yicheng Chen
wiley   +1 more source

The diversity ofSNCAtranscripts in neurons, and its impact on antisense oligonucleotide therapeutics

Evans JR, Gustavsson EK, Doykov I, Murphy D, Virdi GS, Lachica J, Röntgen A, Murtada MH, Pang CW, Macpherson H, Wernick AI, Toomey CE, Athauda D, Choi ML, Hardy J, Wood NW, Vendruscolo M, Mills K, Heywood W, Ryten M, Gandhi S.   +20 more
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antisense Oligonucleotides

Nephron Experimental Nephrology, 1998
Antisense technology was developed to inhibit gene expression by utilizing an oligonucleotide complementary to the mRNA which encodes the target gene. There are a few possible mechanisms for the inhibitory effects of antisense oligonucleotides. Among them, degradation of mRNA by RNase H is considered to be the major mechanism of action for antisense ...
N, Kashihara, Y, Maeshima, H, Makino
openaire   +2 more sources

Pharmacokinetics of Antisense Oligonucleotides

Clinical Pharmacokinetics, 1995
Antisense oligonucleotides are promising therapeutic agents for the treatment of life-threatening diseases. Intravenous injection of phosphodiester oligonucleotide analogue (P-oligonucleotide) in monkeys shows that the oligonucleotide is degraded rapidly in the plasma with a half-life of about 5 minutes.
Wayne M. Galbraith, Jin-Yan Tang, Sudhir Agrawal, Jamal Temsamani   +3 more
openaire   +2 more sources

Antisense oligonucleotides in cancer

Current Opinion in Oncology, 2014
Over the past several dozen years, regardless of the substantial effort directed toward developing rational oligonucleotide strategies to silence gene expression, antisense oligonucleotide-based cancer therapy has not been successful. This review focuses on the most likely reasons for this lack of success, and on the barriers that still need to be ...
Daniela Castanotto, Cy A. Stein
openaire   +3 more sources